MaxCyte, Inc. - Correction: Vesting of RSUs and PDMR Dealing

MaxCyte, Inc.

("MaxCyte" or the "Company")

Vesting of RSUs and PDMR Dealing

The following amendment has been made to the Publication of Vesting of RSUs and PDMR Dealing released on 26 March 2025 at 07:00 under RNS number 1474C.

The RNS did not include the number of shares of previously granted restricted stock units.

All other details remain unchanged.

The full amended text is shown below.

Rockville, Maryland - 26 March 2025: MaxCyte Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics, announces that on 18 March 2025, as per a filing lodged with the U.S. Securities and Exchange Commission, that 20,313 shares of previously granted restricted stock units ("RSUs") vested to Douglas Swirsky, Chief Financial Officer of the Company ("Vesting"). Contemporaneously, 6,939 of the newly vested shares were sold to cover withholding tax due upon the vesting. Such "sale to cover" was automatically effected to satisfy withholding tax liabilities and does not represent a discretionary trade by Mr. Swirsky. The 20,313 new shares of Common Stock were issued pursuant to the Company's existing block admission facility and were sold by Mr. Swirsky at a price range between $3.140 and $3.215 per Common Stock ("Sale"). The sold shares represent approximately 2.2% of Mr. Swirsky's total equity and option holdings in the Company's stock capital, respectively.

Following the Vesting and Sale, Mr. Swirsky holds 13,374 shares of Common Stock representing 2.2% of the issued stock capital of the Company. Mr. Swirsky holds a further 725,000 options over Common Stock, 98,437 RSUs, and 68,750 Performance Stock Units.

The information in the tables below is provided in accordance with the requirements of the UK Market Abuse Regulation.

About MaxCyte

At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients' lives. We have spent more than 25 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today's processes to innovate tomorrow's solutions. Our ExPERT™ platform, which is based on our Flow Electroporation® technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™ and VLx ™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology platform, as well as scientific, technical and regulatory support, we aim to guide them on their journey to transform human health. Learn more at maxcyte.com and follow us on X and LinkedIn.

MaxCyte Contacts:

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM